Table 3.
Subjects, No. (%) |
||
Follow-up Period and Outcome | Meglumine Antimoniate (n = 58) | Miltefosine (n = 58) |
End of treatmenta | ||
Apparent cure | 17 (29.8) | 27 (47.4) |
Improvement | 39 (68.4) | 30 (52.6) |
Early failure | 1 (1.8) | 0 (0) |
Withdrawal without completion of treatment | 1 (1.8) | 1 (1.8) |
Total | 58 | 58 |
Week 13 | ||
Initial therapeutic response | 41 (70.6) | 53 (91.3) |
Therapeutic failure at week 13 | 10 (17.2) | 4 (6.9) |
Unavailable for follow-up | 1 (1.8) | 0 |
Early failure | 1 (1.8) | 0 |
Did not attend week 13 visit | 4 (6.9) | 0 |
Withdrawal without completion of treatment | 1 (1.8) | 1 (1.8) |
Total | 58 | 58 |
Week 26 | ||
Final therapeutic response | 40 (68.9) | 48 (82.8) |
Therapeutic failure at week 26 | 5 (8.6) | 3 (5.2) |
Early failure | 1 (1.8) | 0 |
Failure at week 13 | 10 (17.2) | 4 (6.9) |
Unavailable for follow-up | 1 (1.8) | 2 (3.4) |
Withdrawal without completion of treatment | 1 (1.8) | 1 (1.8) |
Total | 58 | 58 |
Case closure | ||
Cure | 40 (69.0) | 48 (82.8) |
Failure | 18 (31.0) | 10 (17.2) |
Total | 58 | 58 |
The treatment period was 20 days for meglumine antimoniate and 28 days for miltefosine.